Methylofenidan en es it fr

Methylofenidan Brand names, Methylofenidan Analogs

Methylofenidan Brand Names Mixture

  • No information avaliable

Methylofenidan Chemical_Formula


Methylofenidan RX_link

Methylofenidan fda sheet

Methylofenidan FDA

Methylofenidan msds (material safety sheet)

Methylofenidan MSDS

Methylofenidan Synthesis Reference

M. Hartmann, L. Panizzon, U.S. Pat. 2,507,631 (1950)

Methylofenidan Molecular Weight

233.306 g/mol

Methylofenidan Melting Point


Methylofenidan H2O Solubility


Methylofenidan State


Methylofenidan LogP


Methylofenidan Dosage Forms

Tablets; Tablets (sustained release)

Methylofenidan Indication

For use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.

Methylofenidan Pharmacology

Methylphenidate is a central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Its mechanisms appear to be similar to those of dextroamphetamine.

Methylofenidan Absorption

Readily absorbed in a biphasic manner. It reaches peak absorption at approximately two hours for the first phase and five hours for the second phase. Bioavailability is low (approximately 30%)

Methylofenidan side effects and Toxicity

Symptoms of overdose include vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, mydriasis, and dryness of mucous membranes. LD50=190mg/kg (orally in mice)

Methylofenidan Patient Information

Methylofenidan Organisms Affected

Humans and other mammals